Exact Sciences Corp EXAS Product Pipeline Analysis, 2018 Update [Report Updated: 31072018] Prices from USD $750

18:07 EDT 1 Oct 2018 | BioPortfolio Reports

Summary


Exact Sciences Corp Exact Sciences is a molecular diagnostic company that focuses on the early detection and prevention of various types of cancers. The company's flagship product, Cologuard test is a noninvasive stoolbased deoxyribonucleic acid DNA screening product indicated for the early detection of colorectal cancer and precancer. It utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer. The company is also working on the development of additional tests for other types of cancers and identified proprietary methylation markers for several major cancers. It operates laboratory facilities in Madison, Wisconsin to process Cologuard tests. Exact Sciences is headquartered in Madison, Wisconsin, the US.


This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


Scope:


The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company Exact Sciences Corp

The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.


Reasons to Buy:


Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research Development strategies

Develop marketentry and market expansion strategies

Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio


Note: Some sections may be missing if data is unavailable for the company

More From BioPortfolio on "Exact Sciences Corp EXAS Product Pipeline Analysis, 2018 Update [Report Updated: 31072018] Prices from USD $750"